@misc{10481/58543,
year = {2019},
month = {10},
url = {http://hdl.handle.net/10481/58543},
abstract = {The objective was to evaluate the effects of 6 months of supplementation with Altilix®,
containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular
risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind,
placebo-controlled study was performed in 100 subjects with MetS with a follow-up period of
6 months; 50 subjects were randomized to Altilix® (26 men and 24 women, mean age 63   8 years)
and the other 50 to placebo (28 men and 22 women, mean age 63   11 years). Anthropometric,
cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up.
Carotid intima-media thickness and endothelial function were assessed by doppler ultrasound and by
flow-mediated dilation of the brachial artery, respectively. The presence and degree of non-alcoholic
fatty liver disease (NAFLD) was assessed by the fatty liver index (FLI), and subjects were divided
into three subgroups: (1) without NAFLD; (2) with borderline NAFLD; and (3) with NAFLD. After
6 months of Altilix® supplementation, we found a significant improvement vs. placebo in most of
the evaluated parameters, including body weight (-2.40% (95% CI -3.79, -1.01); p < 0.001), waist
circumference (-2.76% (95% CI -4.55, -0.96); p = 0.003), HbA1c (-0.95% (95% CI -1.22, -0.67);
p < 0.001), plasma lipids, FLI (-21.83% (95% CI -27.39, -16.27); p < 0.001), hepatic transaminases,
flow-mediated dilation (10.56% (95% CI 5.00, 16.12); p < 0.001), and carotid intima-media thickness
(-39.48% (95% CI -47.98, -30.97); p < 0.001).},
publisher = {MDPI},
keywords = {Cardiovascular diseases},
keywords = {Metabolic syndrome},
keywords = {Non-alcoholic fatty liver disease},
keywords = {Diabetes mellitus},
keywords = {Dietary supplements},
keywords = {Cynara},
title = {Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study},
doi = {10.3390/nu11112580},
author = {Castellino, Giuseppa and Magán Fernández, Antonio},
}